KEZIA CORREA: Open Payments
NPI 1649928144 · EDINBURG, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,476 in 140 payments from 24 companies in 2025. Trend: 2023 $1,346 · 2024 $3,129 · 2025 $4,476
Food & beverage: $4,476
| Company | Payments | Amount |
|---|---|---|
| Abbott Laboratories | 21 | $923 |
| Dexcom, Inc. | 11 | $509 |
| Novo Nordisk Inc | 15 | $414 |
| Corcept Therapeutics | 24 | $374 |
| Mannkind Corporation | 5 | $298 |
| Lilly USA, LLC | 14 | $264 |
| Insulet Corporation | 3 | $249 |
| Amgen Inc. | 18 | $176 |
| Madrigal Pharmaceuticals | 3 | $167 |
| Ascensia Diabetes Care Us Inc. | 5 | $156 |
Products named: FREESTYLE LIBRE, Dexcom G6 Transmitter, Korlym, FREESTYLE LIBRE 3, AFREZZA, Ozempic, Omnipod, REZDIFFRA.
Industry payments across TX — which companies pay providers there.
